BNP Testing in Heart Failure - One Fits All?

Journal of Clinical and Basic Cardiology

Volumn 6, Issue 1-4, 2003, Pages 15-18

  Stanek, Brigitte ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

BNP; Heart failure; N BNP; Prognosis; Therapeutic implications

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; NATRIURETIC FACTOR; PERINDOPRIL; QUINAPRIL; TRANDOLAPRIL;

CLINICAL TRIAL; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG MEGADOSE; HEART DISEASE; HEART FAILURE; HORMONE DETERMINATION; HUMAN; OUTPATIENT; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCREENING TEST; SUDDEN DEATH;

EID: 0142257149     PISSN: 15612775     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Braunwald E, Harrison DC, Chidsey CA. The heart as an endocrine organ. Am J Med 1964; 36: 1-4.
2. DeBold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci 1981; 28: 89-94.
3. Levin ER, Gardner DG, Samson WK. Natriuretic peptides (Review). N Engl J Med 1998; 339: 321-8.
4. Jensen KT, Carstens J, Pedersen EB. Effect of BNP on renal hemodynamic, tubular function and vasoactive hormones in humans. Am J Physiol 1998; 274: P63-P72.
5. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332: 78-81.
6. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jongasaki M, Ogawa H, Okomura K, Mukoyama M, Nakao K. Localization and mechanisms of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203.
7. Stingo AJ, Clavell AL, Aarhus LL, Burnett JC. Cardiovascular and renal actions of C-type natriuretic peptide. Am J Physiol 1992; 262: H308-H312.
8. Saito Y, Nakao K, Arai H, Nishimura K, Okomura K, Obata K, Takemura G, Fijiwasa H, Sagawa A, Yamada T, Itoh H, Mukoyama M, Hosoda K, Chuichi K, Ban T, Yasue H, Imura H. Augmented expression of atrial natriuretic poly peptide gene in ventricle of human failing heart. J Clin Invest 1989; 83: 298-305.
9. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol 1997; 47: 287-96.
10. Mair J, Friedl W, Thomas S, Puschendorf B. Natriuretic peptides in assessment of left ventricular dysfunction. Scand J Clin Lab Invest Suppl 1999; 230: 132-42.
11. Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, Nishino K, Yoshimasa T, Nakao K. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy: Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 1995; 96: 1280-7.
12. Bruneau BG, Piazza LA, DeBold AJ. BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria. Am J Physiol 1997; 273: 2678-86.
13. Doyama K, Fukumoto M, Takemura G, Tanaka M, Oda T, Hasegawa K, Inada T, Ohtani S, Fujiwara T, Itoh H, Nakao K, Sasayama S, Fujiwara H. Expression and distribution of BNP in human right atria. J Am Coll Cardiol 1998; 32: 1832-8.
14. Luchner A, Stevens TL, Bargeson DD. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998; 274: 1684-9.
15. Harada M, Saito Y. Kuwahara K, Ogawa E, Ishikawa M, Nakagawa O, Miyamoto Y, Kamitani S, Hamanaka I, Kajiyama U, Takashi N, Masuda I, Itoh H, Nakao K. Interaction of myocytes and nonmyocytes is necessary for mechanical stretch to induce ANP/BNP production in cardiocyte culture. J Cardiovasc Pharmacol 1998; 31 (Suppl I): S357-S359.
16. Kunahara K, Saito Y, Ogawa Y, Tamura N, Ishikawa M, Harada M, Ogawa E, Miyamoto Y, Hamanaka I, Kamitani S, Kajiyama N, Takahashi N, Nakagawa O, Masuda I, Nakao K. Endothelin-1 and cardiotrophin-1 induce BNP gene expression by distinct transcriptional mechanisms. J Cardiovasc Pharmacol 1998; 31 (Suppl I): S354-S356.
17. Lerman A, Gibbons RJ, Rodeheffer RJ, Bailey KR, McKinley LJ, Heublein DM Burnett JC jr. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993; 341: 1105-9.
18. Wallen T, Landahl S, Hedner T, Hall C. Atrial peptides, ANP (1-98) and ANP (99-126) in health and disease in an elderly population. Eur Heart J 1993; 14: 1508-13.
19. Davidson NC, Naas AA, Hanso JK, Kennedy NSJ, Coutie WJ, Struthers AD. Comparison of atrial natriuretic peptide, and the N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 1996; 77: 828-31.
20. Yamamoto K, Burnett JC, Jougasaki M, Nishimura RA, Bailey KR, Saito Y, Nakao K, Redfield MM. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28: 988-94.
21. Friedl W, Mair J, Thomas S, Pichler M, Puschendorf B. Natriuretic peptides and cyclic guanosine 3′,5′-monophosphate in asymptomatic and symptomatic left ventricular dysfunction. Heart 1997; 76: 129-36.
22. Cowie MR, Struthers AD, Wood DA, Coats AJS, Thompson SG, Poole-Wilson PA, Sutton GC. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349-53.
23. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Mabuchi N, Hayashi M, Ohnishi M, Sawaki M, Fijii M, Horie H, Sugimoto Y, Kinoshita M. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Eur Heart J 1999; 20: 1799-807.
24. Campbell DJ, Mitchelhill KI, Schlicht SM, Booth RJ. Plasma amino-terminal pro-brain natriuretic peptide: a novel approach to the diagnosis of cardiac dysfunction. J Card Fail 2000; 6: 130-9.
25. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: 825-32.
26. Fruhwald FM, Fahrleitner A, Watzinger N, Fruhwald S, Dobnig H, Schumacher M, Maier R, Zweiker R, Klein WW. Natriuretic peptides in patients with diastolic dysfunction due to idiopathic dilated cardiomyopathy. Eur Heart J 1999; 20: 1415-23.
27. Choy AM, Darbar D, Lang CC, Pringle TH, McNeill GP, Kennedy NS, Struthers AD. Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohumoral methods. Br Heart J 1994; 72: 16-22.
28. McDonagh. Biochemical detection of left ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
29. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnisi M, Sugimoto Y, Kinoshita M. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-16.
30. Sturm B, Pacher R, Strametz-Juranek J, Berger R, Frey B, Stanek B. Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril. Eur J Heart Fail 2000; 2: 407-12.
31. Stanek B, Frey B, Hülsmann M, Berger R, Sturm B, Strametz-Juranek J, Bergler-Klein J, Moser P, Bojic A, Hartter E, Pacher R. Prognostic evaluation of neurohumoral plasma levels before and during β-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001; 38: 436-42.
32. Berger R, Hülsmann M, Strecker K, Bojic A, Stanek B, Pacher R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392-7.
33. Murdoch DR, McDonagh TA, Byrne J, Blue L, Farmer R, Morton JJ, Dargie HJ. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 1999; 138: 1126-32.
34. Brunner-La Rocca HP, Weilenmann D, Kiowski W, Maly Fe, Candinas R, Follath F. Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. Am Heart J 1999; 138: 654-62.
35. Bergler-Klein J, Pacher R, Berger R, Bojic A, Stanek B. Neurohumoral and hemodynamic effects of the selective endothelin antagonist darusentan in advanced chronic heart failure. J Heart Lung Transplant, in press.
36. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls GA, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-30.
37. Daggubati S, Parks JR, Overton RM, Cintron G, Schocken DD, Vesely DL. Adrenomedullin, endothelin, neuropeptide Y. atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. Cardiovasc Res 1997; 36: 246-55.
38. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Ikram H, Crozier JG, Smyth DW. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97: 1921-9.
39. Nagaya N, Goto Y, Nishikimi T, Uematsu M, Miyao Y, Kobayashi Y, Miyazaki S, Hamada S, Kuribayashi S, Takamiya M, Matsuo H, Kangawa K, Nonogi H. Sustained elevation of plasma brain natriuretic peptide levels associated with progressive ventricular remodelling after acute myocardial infarction. Clin Sci 1999; 96: 129-36.
40. Cheng VL, Krishnaswamy P, Kazanegra R, Garcia A, Gardetto N, Maisel AS. A rapid bedside test for B-type natriuretic peptide predicts treatment outcomes in patients admitted with decompensated heart failure. J Am Coll Cardiol 2001; 37: 386-91.
41. Cleland JGF. Screening for left ventricular dysfunction and chronic heart failure. Should it be done and, if so, how? In: Stanek B (ed). Optimising Heart Failure Management. Adis International, Auckland, 2000: 1-17.
42. Colluci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AP, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught HW, LeJemtel TH for the nesiritide study group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000; 343: 246-53.